

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/003030

International filing date: 22 March 2005 (22.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0406378.0
Filing date: 22 March 2004 (22.03.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

EP/05/3030


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Andrew Jersey

Dated 9 March 2005



23MAR04 E882923-1 D00001
F01/7700 0.00-0406378.0 CHERIE**Request for grant of a patent**(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help you fill in
this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 10182 GB PAB

2. Patent application number
(The Patent Office will fill this part in)

0406378.0

22 MAR 2004

3. Full name, address and postcode of the or of
each applicant (underline all surnames)Karo Bio AB
Novum
S-141 57 Huddinge
Sweden

6477 871002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation Sweden

4. Title of the invention NOVEL PHARMACEUTICAL COMPOSITIONS

5. Name of your agent (if you have one) Abel & Imray

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)
20 Red Lion Street
London
WC1R 4PQ
United Kingdom

Patents ADP number (if you know it)

174001 ✓

6. Priority: Complete this section if you are
declaring priority from one or more earlier
patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)Date of filing
(day / month / year)7. Divisionals, etc: Complete this section only if
this application is a divisional application or
resulted from an entitlement dispute (see note f)Number of earlier UK application
(day / month / year)8. Is a Patents Form 7/77 (Statement of
inventorship and of right to grant of a patent)
required in support of this request?

YES

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form -

Description 67 ✓
Claim(s) 8 ✓ *JML*
Abstract 1 ✓ *JML*
Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination
(Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Abel & Imray

Date 22 March 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Paul Brady - 020 7242 9984
paul.brady@patentable.co.uk

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Novel Pharmaceutical Compositions

Field of the invention

The present invention relates to compounds which are agonists or partial agonists of the

5 thyroid receptor and the use of such compounds for therapeutic purposes

Background of the invention

While the extensive role of thyroid hormones in regulating metabolism in humans is well recognized, the discovery and development of new specific drugs for improving the

10 treatment of hyperthyroidism and hypothyroidism has been slow. This has also limited the development of thyroid agonists and antagonists for treatment of other important clinical indications, such as hypercholesterolemia, dyslipidemia, obesity, diabetes, atherosclerosis and cardiac diseases.

15 Thyroid hormones affect the metabolism of virtually every cell of the body. At normal levels, these hormones maintain body weight, metabolic rate, body temperature and mood, and influence blood levels of serum lipoproteins. Thus, in hypothyroidism there is weight gain, high levels of LDL cholesterol, and depression. In hyperthyroidism, these hormones lead to weight loss, hypermetabolism, lowering of serum LDL cholesterol
20 levels, cardiac arrhythmias, heart failure, muscle weakness, bone loss in postmenopausal women, and anxiety.

Thyroid hormones are currently used primarily as replacement therapy for patients with hypothyroidism. Therapy with L-thyroxine returns metabolic functions to normal and
25 can easily be monitored with routine serum measurements of levels of thyroid-stimulating hormone (TSH), thyroxine (3,5,3',5'-tetraiodo-L-thyronine, or T₄) and triiodothyronine (3,5,3'-triiodo-L-thyronine, or T₃). However, replacement therapy, particularly in older individuals, may be restricted by certain detrimental effects from thyroid hormones.

30 In addition, some effects of thyroid hormones may be therapeutically useful in non-thyroid disorders if adverse effects can be minimized or eliminated. These potentially

useful influences include for example, lowering of serum LDL levels, weight reduction, amelioration of depression and stimulation of bone formation. Prior attempts to utilize thyroid hormones pharmacologically to treat these disorders have been limited by manifestations of hyperthyroidism, and in particular by cardiovascular toxicity.

5

Furthermore, useful thyroid agonist drugs should minimize the potential for undesired consequences due to locally induced hypothyroidism, i.e. sub-normal levels of thyroid hormone activity in certain tissues or organs. This can arise because increased circulating thyroid hormone agonist concentrations may cause the pituitary to suppress the secretion of thyroid stimulating hormone (TSH), thereby reducing thyroid hormone synthesis by the thyroid gland (negative feedback control). Since endogenous thyroid hormone levels are reduced, localized hypothyroidism can result wherever the administered thyroid agonist drug fails to compensate for the reduction in endogenous hormone levels in specific tissues.

10

Development of specific and selective thyroid hormone receptor ligands, particularly agonists of the thyroid hormone receptor, is expected to lead to specific therapies for these common disorders, while avoiding the cardiovascular and other toxicity of native thyroid hormones. Tissue-selective thyroid hormone agonists may be obtained by

20

selective tissue uptake or extrusion, topical or local delivery, targeting to cells through other ligands attached to the agonist and targeting receptor subtypes. Tissue selectivity can also be achieved by selective regulation of thyroid hormone responsive genes in a tissue specific manner.

25

Accordingly, the compounds that are thyroid hormone receptor ligands, particularly selective agonists of the thyroid hormone receptor, are expected to demonstrate a utility for the treatment or prevention of diseases or disorders associated with thyroid hormone activity, for example: (1) hypercholesterolemia, dyslipidemia or any other lipid disorder manifested by an unbalance of blood or tissue lipid levels ; (2) atherosclerosis; (3)

30

replacement therapy in elderly subjects with hypothyroidism who are at risk for cardiovascular complications; (4) replacement therapy in elderly subjects with subclinical


hypothyroidism who are at risk for cardiovascular complications; (5) obesity; (6) diabetes (7) depression; (8) osteoporosis (especially in combination with a bone resorption inhibitor); (9) goiter; (10) thyroid cancer; (11) cardiovascular disease or congestive heart failure; (12) glaucoma; and (13) skin disorders.

5

Summary of the invention

The present invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt,

10



wherein:

15 R^1 is selected from $-\text{SO}_2\text{R}^6$, $-\text{SOR}^6$ and $-\text{C}(\text{O})\text{R}^6$;

20 R^6 is selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl-
 C_{1-3} alkyl, C_{5-7} aryl and C_{1-7} heterocyclyl, said alkyl, alkenyl or alkynyl optionally being
 substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, methoxy
 or methoxy substituted with 1 to 3 halogen atoms; said cycloalkyl, aryl or heterocyclyl
 optionally being substituted with 1, 2 or 3 groups independently selected from halogen,
 hydroxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, methoxy, or methoxy or C_{1-4} alkyl
 substituted with 1 to 3 halogen atoms;

25 Each R^2 is independently selected from halogen, mercapto, nitro, cyano, alkoxy, $-\text{CO}_2\text{R}^c$,
 $-\text{CONHR}^c$, $-\text{CHO}$, $-\text{SO}_2\text{R}^6$, $-\text{SO}_2\text{NHR}^6$, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, NHR^1 and

NH(R¹)₂, said alkyl, alkenyl, alkynyl or alkoxy optionally being substituted with 1, 2 or 3 groups selected from halogen, hydroxy, methoxy, C₁₋₄ alkoxy, C₁₋₄ alkylthio, mercapto, nitro, cyano or methoxy substituted with 1 to 3 halogen atoms;

5 n is 0, 1, 2 or 3;

Y and Y' are independently selected from oxygen, sulphur or -CH(R^a)-, with the proviso that at least one of Y and Y' is -CH(R^a)- and the further proviso that when one of Y and Y' is oxygen or sulphur, then R^a is hydrogen, halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, fluoromethyl, difluoromethyl, trifluoromethyl;

10 R^a is selected from hydrogen, halogen, hydroxy, mercapto, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy or trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio or thiotrifluoromethyl;

15 R³ and R⁴ are independently selected from halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, fluoromethyl, difluoromethyl, trifluoromethyl, C₁₋₄ alkoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio or trifluoromethylthio;

20 W is selected from C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, N(R^b)-C₁₋₃ alkylene, C(O)-C₁₋₃ alkylene, S-C₁₋₃ alkylene, O-C₁₋₃ alkylene, C(O)NH-C₁₋₃ alkylene or NH(CO)-C₀₋₃ alkylene, said alkylene, alkenylene or alkynylene optionally being substituted with 1 or 2 groups selected from hydroxy, mercapto, amino, halo, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ alkyl substituted with 1, 2 or 3 halogen atoms, and C₁₋₃ alkoxy substituted with 1, 2 or 3 halogen atoms;

25 R^b is selected from hydrogen, hydroxy, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy;

R^5 is selected from $-CO_2R^c$, $-PO(OR^c)_2$, $-PO(OR^c)NH_2$, $-SO_2OR^c$, $-COCO_2R^c$, $CONR^cOR^c$, $-SO_2NHR^c$, $-NHSO_2R^c$, $-CONHSO_2R^c$, and $-SO_2NHCOR^c$;

- 5 Each R^c is independently selected from hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl and C_{2-4} alkynyl;

R^c' is selected from R^c , C_{5-10} aryl and C_{5-10} aryl substituted with amino, hydroxy, halogen or C_{1-4} alkyl.

10

- Compounds of the invention have surprisingly been found to be ligands of the thyroid receptor, in particular agonists or partial agonists of the thyroid receptor. The compounds accordingly have use in the treatment or prophylaxis of conditions associated with thyroid receptor activity.

15

Detailed description of the invention

- The compounds of formula (I) may contain chiral (asymmetric) centres. The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are within the scope of the present invention.

20 Preferably, R^1 is selected from $-SO_2R^6$, and $-C(O)R^6$;

- 25 Preferably, R^6 is selected from C_{1-8} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, C_6 aryl and C_{3-7} heterocyclyl. Preferred substituents for said alkyl or alkenyl include groups independently selected from halogen, methoxy or halomethoxy. Preferred substituents for said cycloalkyl, aryl or heterocyclyl include halogen, methyl, ethyl, methoxy or methyl substituted with 1 to 3 halogen atoms;

- 30 More preferably, R^6 is selected from C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-4} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, unsubstituted C_6 aryl, and C_{3-5} heterocyclyl.

When R¹ is SO₂R⁶, R⁶ is preferably selected from phenyl, methyl, ethyl, propyl or 3,5 dimethyl isoxazole, for example methyl, ethyl and propyl. When R¹ is C(O)R⁶, R⁶ is preferably selected from methyl, ethyl, propyl, cyclobutyl, cyclopropyl, or i-propyl.

5

R² is preferably selected from halogen, C₁₋₂ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, nitro, cyano, C₁₋₂ alkoxy and C₁₋₂ alkyl substituted with 1, 2 or 3 halogen atoms. More preferably, R² is selected from halogen, methyl, trifluormethyl, difluoromethyl or fluoromethyl. When R² is a halogen, it is preferably selected from bromine, chlorine and fluorine, especially 10 chlorine.

10

Preferably n is 0, 1 or 2. More preferably, n is 0 or 1, for example 0.

Preferably, Y is O or S, and Y' is CH(R^a). Most preferably, Y is O and Y' is CH(R^a).

15

R^a is preferably selected from hydrogen, halogen, C₁₋₂ alkyl, fluoromethyl, difluoromethyl and trifluoromethyl. Most preferably, R^a is hydrogen.

20

R³ and R⁴ are preferably independently selected from halogen, C₁₋₄ alkyl, fluoromethyl, difluoromethyl and trifluoromethyl. More preferably, R³ and R⁴ are independently selected from halogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl. Amongst the halogens, there are preferred bromine, chlorine and fluorine, especially bromine and chlorine, in particular bromine.

25

R³ and R⁴ may simultaneously represent the same radical. Alternatively, R³ and R⁴ are different from each other.

30

W is preferably selected from C₁₋₃ alkylene, C₂₋₃ alkenylene, N(R^b)-C₁₋₂ alkylene, C(O)-C₁₋₂ alkylene, S-C₁₋₂ alkylene, O-C₁₋₂ alkylene, C(O)NH-C₀₋₂ alkylene or NH(CO)-C₁₋₂ alkylene, said alkylene or alkenylene optionally being substituted with a group selected from hydroxy, mercapto, amino or halo, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkyl substituted

with 1, 2 or 3 halogen atoms, and C₁₋₂ alkoxy substituted with 1, 2 or 3 halogen atoms. More preferably, W is selected from C₁₋₃ alkylene, C(O)-C₁₋₂ alkylene, C(O)NH-C₁₋₂ alkylene or NH(CO)-C₁₋₂ alkylene. Most preferably W is ethylene or C(O)NH-CH₂-.


5 R^b is preferably selected from hydrogen, C₁₋₂ alkyl, fluoromethyl, difluoromethyl and trifluoromethyl;

R⁵ is preferably selected from -CO₂R^c, -PO(OR^c)₂, -SO₂OR^c, -COCO₂R^c, CONR^cOR^c and -NHSO₂R^c. More preferably, R⁵ is -CO₂R^c, -PO(OR^c)₂ or -SO₂OR^c. Most preferably, R⁵ 10 is -CO₂R^c, particularly -CO₂H.

R^c is preferably ethyl, methyl or hydrogen, particularly hydrogen.

R^{c'} is preferably selected from R^c, phenyl and phenyl substituted with amino, hydroxyl, 15 halogen or methyl.

Accordingly, one preferred group of compounds of the invention includes compounds according to formula (Ia) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or 20 salts



25 wherein:

R¹ is selected from -SO₂R⁶ and -C(O)R⁶;

R⁶ is selected from C₁₋₈ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, C₆ aryl and C₃₋₇ heterocyclyl, said alkyl or alkenyl optionally being substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, methoxy or halomethoxy; said
5 cycloalkyl, aryl or heterocyclyl optionally being substituted with 1, 2 or 3 groups independently selected from halogen, methyl, methoxy, or methoxy substituted with 1 to 3 halogen atoms;

Each R² is independently selected from halogen, C₁₋₂ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl C₁₋₂
10 alkoxy and C₁₋₂ alkyl substituted with 1, 2 or 3 halogen atoms;

n is 0, 1 or 2;

Y is O or S, and Y' is CH(R^a);

15 R^a is selected from hydrogen, halogen, C₁₋₂ alkyl, fluoromethyl, difluoromethyl and trifluoromethyl;

20 R³ and R⁴ are independently selected from halogen, C₁₋₄ alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C₁₋₄ alkoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio or trifluoromethylthio;

25 W is selected from C₁₋₃ alkylene, C(O)-C₁₋₂ alkylene, C(O)NH-C₁₋₂ alkylene or NH(CO)-C₁₋₂ alkylene;

30 R⁵ is selected from -CO₂R^c, -PO(OR^c)₂, -SO₂OR^c, -COCO₂R^c, CONR^cOR^c and -NHSO₂R^c;

30 Each R^c is independently selected from hydrogen and C₁₋₄ alkyl; and

R^c' is selected from R^c , phenyl and phenyl substituted with amino, hydroxyl, halogen or methyl.

5 Preferred compounds according to the invention include:

3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)propanoic acid

N-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dibromobenzoyl)glycine

3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dibromophenyl)propanoic acid

10 acid

3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid

N-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromobenzoyl)glycine

3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid

3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dichlorophenyl)propanoic acid

15 N-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromobenzoyl)glycine

3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid

3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)-2-fluoropropanoic acid

3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorophenyl)-2-fluoropropanoic acid

20 3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dichlorophenyl)-2-fluoropropanoic acid

3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dibromophenyl)-2-fluoropropanoic acid

3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)-2-fluoropropanoic acid

3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)-2-fluoropropanoic acid

25 (4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)acetic acid

N-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorobenzoyl)glycine

(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dibromophenyl)acetic acid

(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorophenyl)acetic acid

N-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorobenzoyl)glycine

30 (4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)acetic acid

(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dichlorophenyl)acetic acid

- N-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)acetic acid
3-[(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)amino]-3-oxopropanoic acid
- 5 3-[(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dibromophenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorophenyl)amino]-3-oxopropanoic acid
- 10 3-[(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
- 15 3-[(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dichlorophenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)amino]-3-oxopropanoic acid
3-[(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dimethylphenyl)amino]-3-
- 20 oxopropanoic acid
(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromophenyl)acetic acid
3-(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
- 25 N-(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-5-fluorobenzyl]oxy}-3,5-dibromophenyl)acetic acid
- 30 3-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dibromobenzoyl)glycine

- 3-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dibromophenyl)acetic acid
- 5 3-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dichlorobenzoyl)glycine
- 10 10 (4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dibromophenyl)acetic acid
3-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromophenyl)acetic acid
- 15 15 N-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dichlorophenyl)acetic acid
3-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
- 20 20 (4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromophenyl)acetic acid
3-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
- 25 25 3-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dichlorophenyl)acetic acid
N-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromophenyl)acetic acid
3-(3,5-dichloro-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic
- 30 acid
N-(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine

- 3-(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- N-(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}benzoyl)glycine
- 5 3-(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dichloro-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- N-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}benzoyl)glycine
- 3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dichloro-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-
- 10 fluoropropanoic acid
- 3-(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 3-(3,5-dichloro-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 15 3-(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 3-(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic
- 20 acid
- (3,5-dichloro-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
- N-(3,5-dichloro-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine
- (3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
- (3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
- 25 N-(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}benzoyl)glycine
- (3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
- (3,5-dichloro-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
- N-(3,5-dichloro-4-{[3-methyl-5-(propionylamino)benzyl]oxy}benzoyl)glycine
- (3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
- 30 3-[(3,5-dichloro-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid

- 3-[(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dimethyl-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 5 3-[(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(4-{[3-chloro-5-(propionylamino)benzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
- 10 3-[(3,5-dichloro-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 15 3-[(3,5-dimethyl-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
(3,5-dichloro-4-{[3-(propionylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-(propionylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-(propionylamino)benzyl]oxy}phenyl)acetic acid
- 20 3-(3,5-dichloro-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}benzoyl)glycine
- 25 25 3-(3,5-dibromo-4-{[3-fluoro-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{[3-cyano-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-cyano-5-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-cyano-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{[3-cyano-5-(propionylamino)benzyl]oxy}phenyl)acetic acid
- 30 30 N-(3,5-dichloro-4-{[3-cyano-5-(propionylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-cyano-5-(propionylamino)benzyl]oxy}phenyl)acetic acid

- 3-(3,5-dichloro-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
5 N-(3,5-dichloro-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{{2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{2-chloro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{{2-chloro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{2-chloro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
10 (3,5-dibromo-4-{{2-chloro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{2-chloro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
(3,5-dichloro-4-{{2-chloro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)propanoic
acid
15 N-(3,5-dibromo-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)propanoic
acid
(3,5-dichloro-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}benzoyl)glycine
20 (3,5-dibromo-4-{{2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic
acid
N-(3,5-dibromo-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic
25 acid
(3,5-dichloro-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{{5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{3-(isobutyrylamino)-5-
30 (trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{{3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine

- 3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dichloro-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
5 3-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dichloro-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)propanoic acid
3-(3,5-dichloro-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-
10 fluoropropanoic acid
3-(3,5-dichloro-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)-2-fluoropropanoic
acid
3-(3,5-dichloro-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)-2-fluoropropanoic
acid
15 3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-
fluoropropanoic acid
3-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)-2-fluoropropanoic
acid
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)-2-fluoropropanoic
20 acid
(3,5-dichloro-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
(3,5-dichloro-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
25 N-(3,5-dichloro-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
(3,5-dichloro-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)acetic acid
30 3-[(3,5-dichloro-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-
3-oxopropanoic acid

- 3-[(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
- 5 3-[(3,5-dichloro-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
- 10 3-[(3,5-dichloro-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 15 3-[(4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
(3,5-dichloro-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
- 20 3-(3,5-dichloro-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
- 25 3-(3,5-dibromo-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
- 30 N-(3,5-dichloro-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-cyano-5-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid

- 3-(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
5 N-(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
10 (3,5-dibromo-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dichloro-4-{{[2-chloro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)propanoic
acid
15 N-(3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)propanoic
acid
(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}benzoyl)glycine
20 (3,5-dibromo-4-{{[2-fluoro-3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)acetic acid
3-(3,5-dichloro-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic
acid
N-(3,5-dibromo-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic
acid
25 (3,5-dichloro-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)acetic acid
30 and

- N-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine
3-[3,5-dichloro-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
- 5 N-[3,5-dibromo-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-[3,5-dichloro-4-({3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
- 10 N-[3,5-dibromo-4-({3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
3-(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid
3-[3,5-dichloro-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]-2-fluoropropanoic acid
- 15 3-[3,5-dichloro-4-({3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]-2-fluoropropanoic acid
3-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid
3-[3,5-dibromo-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]-2-
- 20 fluoropropanoic acid
3-[3,5-dibromo-4-({3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]-2-fluoropropanoic acid
(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
- 25 N-(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}benzoyl)glycine
(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)acetic acid
[3,5-dichloro-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
- 30 N-[3,5-dichloro-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid

- [3,5-dichloro-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
[3,5-dibromo-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-[(3,5-dichloro-4-{3-[(methylsulfonyl)amino]-5-
5 (trifluoromethyl)benzyl}oxy)phenyl]amino]-3-oxopropanoic acid
3-[(3,5-dibromo-4-{3-[(methylsulfonyl)amino]-5-
(trifluoromethyl)benzyl}oxy)phenyl]amino]-3-oxopropanoic acid
3-[(3,5-dimethyl-4-{3-[(methylsulfonyl)amino]-5-
(trifluoromethyl)benzyl}oxy)phenyl]amino]-3-oxopropanoic acid
10 3-{[3,5-dichloro-4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-
oxopropanoic acid
3-{[3,5-dibromo-4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-
oxopropanoic acid
3-{[4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]-3,5-dimethylphenyl]amino}-3-
15 oxopropanoic acid
3-{[3,5-dichloro-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-
oxopropanoic acid
3-{[3,5-dibromo-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-
oxopropanoic acid
20 3-{[3,5-dimethyl-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-
oxopropanoic acid
[3,5-dichloro-4-(3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
[3,5-dibromo-4-(3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
25 3-[3,5-dichloro-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic
acid
N-[3,5-dibromo-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
3-[3,5-dibromo-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic
acid
30 [3,5-dichloro-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine

- [3,5-dibromo-4-(3-fluoro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-[3,5-dichloro-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
- N-[3,5-dibromo-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
5 3-[3,5-dibromo-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
[3,5-dichloro-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
[3,5-dibromo-4-(3-cyano-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
- 10 3-[3,5-dichloro-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
N-[3,5-dibromo-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
3-[3,5-dibromo-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
- 15 [3,5-dichloro-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
[3,5-dibromo-4-(2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-[3,5-dichloro-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
- 20 N-[3,5-dibromo-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
3-[3,5-dibromo-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
[3,5-dibromo-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
N-[3,5-dichloro-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
- 25 [3,5-dichloro-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-[3,5-dichloro-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
N-[3,5-dibromo-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
- 30 3-[3,5-dibromo-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

- [3,5-dichloro-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
- N-[3,5-dichloro-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl] glycine
- 5 [3,5-dibromo-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-[3,5-dichloro-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl] propanoic acid
- N-[3,5-dibromo-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]
- 10 glycine
3-[3,5-dibromo-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl] propanoic acid
[3,5-dichloro-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
- 15 N-[3,5-dichloro-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl] glycine
[3,5-dibromo-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]acetic acid
3-(3,5-dichloro-4-{3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)
- 20 propanoic acid
N-(3,5-dibromo-4-{3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}benzoyl) glycine
3-[3,5-dichloro-4-(3-chloro-5-[(ethylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
N-[3,5-dibromo-4-(3-chloro-5-[(ethylsulfonyl)amino]benzyl)oxy]benzoyl]glycine
- 25 3-[3,5-dibromo-4-(3-chloro-5-[(ethylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid
3-[3,5-dichloro-4-(3-[(ethylsulfonyl)amino]-5-methylbenzyl)oxy]phenyl]propanoic acid
N-[3,5-dibromo-4-(3-[(ethylsulfonyl)amino]-5-methylbenzyl)oxy]benzoyl]glycine
3-[3,5-dibromo-4-(3-[(ethylsulfonyl)amino]-5-methylbenzyl)oxy]phenyl]propanoic acid
3-(3,5-dichloro-4-{3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)-2-
- 30 fluoropropanoic acid

- 3-[3,5-dichloro-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]-2-fluoropropanoic acid
- 3-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]-2-fluoropropanoic acid
- 5 3-(3,5-dibromo-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)-2-fluoropropanoic acid
- 3-[3,5-dibromo-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]-2-fluoropropanoic acid
- 3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]-2-fluoropropanoic acid
- 10 3-[3,5-dibromo-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl]acetic acid
(3,5-dichloro-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)acetic acid
N-(3,5-dichloro-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}benzoyl)glycine
- 15 (3,5-dibromo-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)acetic acid
[3,5-dichloro-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
- 20 [3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]acetic acid
3-[(3,5-dichloro-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)amino]-3-oxopropanoic acid
- 25 3-[(3,5-dibromo-4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}phenyl)amino]-3-oxopropanoic acid
3-[(4-{ [3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl}oxy}-3,5-dimethylphenyl)amino]-3-oxopropanoic acid
3-{ [3,5-dichloro-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]amino}-3-
- 30 oxopropanoic acid

- 3-[{3,5-dibromo-4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]amino}-3-oxopropanoic acid
- 3-[{4-({3-chloro-5-[(ethylsulfonyl)amino]benzyl}oxy)-3,5-dimethylphenyl]amino}-3-oxopropanoic acid
- 5 3-[{3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]amino}-3-oxopropanoic acid
- 3-[{3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)phenyl]amino}-3-oxopropanoic acid
- 3-[{4-({3-[(ethylsulfonyl)amino]-5-methylbenzyl}oxy)-3,5-dimethylphenyl]amino}-3-oxopropanoic acid
- 10 oxopropanoic acid
[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
3-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]propanoic acid
- 15 N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]propanoic acid
[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]acetic acid
- 20 3-[3,5-dichloro-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
[3,5-dichloro-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
- 25 [3,5-dibromo-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
3-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]propanoic acid
[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]acetic acid
- 30 N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)benzoyl]glycine
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]acetic acid

- 3-[3,5-dichloro-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
[3,5-dibromo-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
- 5 N-[3,5-dichloro-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
[3,5-dichloro-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]acetic acid
3-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]
propanoic acid
N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)benzoyl]
- 10 glycine
3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]
propanoic acid
[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]acetic
acid
- 15 N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)benzoyl]
glycine
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]acetic
acid
3-[3,5-dichloro-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]
- 20 propanoic acid
N-[3,5-dibromo-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)benzoyl]
glycine
3-[3,5-dibromo-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]
propanoic acid
- 25 [3,5-dichloro-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]acetic
acid
N-[3,5-dichloro-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)benzoyl]
glycine
[3,5-dibromo-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]acetic
- 30 acid

More preferred compounds according to the invention include:

- 3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)propanoic acid
3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
5 3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)-2-fluoropropanoic acid
3-[(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)amino]-3-oxopropanoic acid
(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorophenyl)acetic acid
10 N-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorobenzoyl)glycine
(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromophenyl)acetic acid
3-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-5-cyanobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
15 N-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
20 3-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromobenzoyl)glycine
3-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dichlorophenyl)propanoic acid
N-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromobenzoyl)glycine
25 3-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
30 3-[(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid

- 3-[(3,5-dichloro-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-[(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 5 3-(3,5-dibromo-4-{[2-chloro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
(3,5-dibromo-4-{[2-fluoro-5-methyl-3-(propionylamino)benzyl]oxy}phenyl)acetic acid
- 10 N-(3,5-dibromo-4-{[5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
- 15 3-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
N-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}benzoyl)glycine
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)propanoic acid
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 20 3-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)-2-fluoropropanoic acid
3-[(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 25 3-[(3,5-dibromo-4-{[3-(isobutyrylamino)-5-methylbenzyl]oxy}phenyl)amino]-3-oxopropanoic acid
3-(3,5-dibromo-4-{[3-fluoro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
3-(3,5-dibromo-4-{[2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
- 30 3-(3,5-dibromo-4-{[2-chloro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid

3-(3,5-dibromo-4-{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid

and

5

N-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}benzoyl) glycine

3-[3,5-dichloro-4-{3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]propanoic acid

10 3-[3,5-dibromo-4-{3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]propanoic acid

3-[3,5-dichloro-4-{3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]propanoic acid

3-(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid

15 3-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid

3-[3,5-dibromo-4-{3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]-2-fluoropropanoic acid

20 3-[3,5-dibromo-4-{3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]-2-fluoropropanoic acid

3-{[3,5-dibromo-4-{3-chloro-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]amino}-3-oxopropanoic acid

25 3-{[3,5-dichloro-4-{3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]amino}-3-oxopropanoic acid

3-{[3,5-dibromo-4-{3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy]phenyl]amino}-3-oxopropanoic acid

3-[3,5-dibromo-4-{2-fluoro-3-[(methylsulfonyl)amino]benzyl}oxy]phenyl]propanoic acid

30 [3,5-dichloro-4-{2-fluoro-3-[(methylsulfonyl)amino]benzyl}oxy]phenyl]acetic acid
N-[3,5-dichloro-4-{2-fluoro-3-[(methylsulfonyl)amino]benzyl}oxy]benzoyl]glycine

- [3,5-dibromo-4-({2-fluoro-3-[{(methylsulfonyl)amino]benzyl}oxy]phenyl}acetic acid
3-[3,5-dibromo-4-({2-chloro-3-[{(methylsulfonyl)amino]benzyl}oxy]phenyl]propanoic
acid
- 5 N-[3,5-dibromo-4-({2-fluoro-5-methyl-3-[{(methylsulfonyl)amino]benzyl}oxy]benzoyl]
glycine
- 3-[3,5-dibromo-4-({2-fluoro-5-methyl-3-[{(methylsulfonyl)amino]benzyl}oxy]phenyl]
propanoic acid
- N-[3,5-dibromo-4-({5-chloro-2-fluoro-3-[{(methylsulfonyl)amino]benzyl}oxy]benzoyl]
glycine
- 10 3-[3,5-dibromo-4-({5-chloro-2-fluoro-3-[{(methylsulfonyl)amino]benzyl}oxy]phenyl]
propanoic acid
- 3-(3,5-dibromo-4-{[3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)
propanoic acid
- N-[3,5-dibromo-4-({3-chloro-5-[{(ethylsulfonyl)amino]benzyl}oxy]benzoyl]glycine
- 15 3-[3,5-dibromo-4-({3-chloro-5-[{(ethylsulfonyl)amino]benzyl}oxy]phenyl]propanoic acid
N-[3,5-dibromo-4-({3-[{(ethylsulfonyl)amino]-5-methylbenzyl}oxy]benzoyl]glycine
- 3-[3,5-dibromo-4-({3-[{(ethylsulfonyl)amino]-5-methylbenzyl}oxy]phenyl]propanoic acid
- 3-(3,5-dibromo-4-{[3-[{(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-
fluoropropanoic acid
- 20 3-[3,5-dibromo-4-({3-chloro-5-[{(ethylsulfonyl)amino]benzyl}oxy]phenyl]-2-
fluoropropanoic acid
- 3-[3,5-dibromo-4-({3-[{(ethylsulfonyl)amino]-5-methylbenzyl}oxy]phenyl]-2-
fluoropropanoic acid
- 3-{[3,5-dibromo-4-({3-chloro-5-[{(ethylsulfonyl)amino]benzyl}oxy]phenyl]amino}-3-
25 oxopropanoic acid
- 3-{[3,5-dibromo-4-({3-[{(ethylsulfonyl)amino]-5-methylbenzyl}oxy]phenyl]amino}-3-
oxopropanoic acid
- [3,5-dichloro-4-({3-[{(ethylsulfonyl)amino]benzyl}oxy]phenyl}acetic acid
- N-[3,5-dichloro-4-({3-[{(ethylsulfonyl)amino]benzyl}oxy]benzoyl]glycine
- 30 [3,5-dibromo-4-({3-[{(ethylsulfonyl)amino]benzyl}oxy]phenyl}acetic acid
3-[3,5-dichloro-4-({3-[{(ethylsulfonyl)amino]-5-fluorobenzyl}oxy]phenyl]propanoic acid

- N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)benzoyl]glycine
3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]propanoic acid
[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]acetic acid
N-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)benzoyl]glycine
5 [3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-5-fluorobenzyl}oxy)phenyl]acetic acid
3-[3,5-dibromo-4-({3-cyano-5-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)benzoyl]glycine
3-[3,5-dichloro-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
10 3-[3,5-dibromo-4-({2-chloro-3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-[3,5-dichloro-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]
propanoic acid
N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)benzoyl]
glycine
15 3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]
propanoic acid
[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}oxy)phenyl]acetic
acid
3-[3,5-dibromo-4-({5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}oxy)phenyl]
20 propanoic acid

Most preferred compounds according to the invention include:

- 3-(4-{[3-(acetylamino)-5-(trifluoromethyl)benzyl]oxy}-3,5-dichlorophenyl)propanoic
acid
25 3-(4-{[3-(acetylamino)-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-5-chlorobenzyl]oxy}-3,5-dibromophenyl)-2-fluoropropanoic acid
3-(4-{[3-(acetylamino)-2-chlorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-2-fluoro-5-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
3-(4-{[3-(acetylamino)-5-chloro-2-fluorobenzyl]oxy}-3,5-dibromophenyl)propanoic acid
30 3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)propanoic acid

- 3-(3,5-dibromo-4-{[3-methyl-5-(propionylamino)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 3-[(3,5-dibromo-4-{[3-(propionylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 5 3-[(3,5-dibromo-4-{[3-chloro-5-(propionylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-(3,5-dibromo-4-{[2-chloro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dibromo-4-{[5-chloro-2-fluoro-3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 10 3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dibromo-4-{[3-(isobutyrylamino)-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid
- 15 3-[(3,5-dibromo-4-{[3-chloro-5-(isobutyrylamino)benzyl]oxy}phenyl)amino]-3-oxopropanoic acid
- 3-(3,5-dibromo-4-{[5-chloro-2-fluoro-3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromophenyl)propanoic acid
- 20 3-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorophenyl)propanoic acid
- 3-(4-{[3-(acetylamino)-4-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid
- 3-(3,5-dibromo-4-{[3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dichloro-4-{[3-(propionylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dibromo-4-{[3-(butyrylamino)benzyl]oxy}phenyl)propanoic acid
- 25 3-(3,5-dibromo-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dichloro-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid
- 3-(3,5-dibromo-4-{[3-(isobutyrylamino)-2-methylbenzyl]oxy}phenyl)propanoic acid
- 3-[3,5-dibromo-4-({3-[(3-methylbutanoyl)amino]benzyl}oxy)phenyl]propanoic acid
- 3-[3,5-dibromo-4-({3-[(2E)-but-2-enoylamino]benzyl}oxy)phenyl]propanoic acid
- 30 3-[3,5-dibromo-4-({3-[(cyclopropylcarbonyl)amino]benzyl}oxy)phenyl]propanoic acid
- 3-[3,5-dibromo-4-({3-[(cyclobutylcarbonyl)amino]benzyl}oxy)phenyl]propanoic acid

3-[3,5-dibromo-4-(3-[(cyclopentylcarbonyl)amino]benzyl)oxy]phenyl]propanoic acid
N-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromobenzoyl)glycine
N-(3,5-dibromo-4-{[3-(propionylamino)benzyl]oxy}benzoyl)glycine
N-(3,5-dibromo-4-{[3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine

5

and

3-[3,5-dibromo-4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

3-[3,5-dichloro-4-(3-methyl-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic

10 acid

3-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid

3-[3,5-dibromo-4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]-2-fluoropropanoic acid

15 3-{[3,5-dibromo-4-(3-chloro-5-[(methylsulfonyl)amino]benzyl)oxy]phenyl]amino}-3-oxopropanoic acid

3-[3,5-dibromo-4-(2-chloro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

20 3-[3,5-dibromo-4-(2-fluoro-5-methyl-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

N-[3,5-dibromo-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]benzoyl]glycine

3-[3,5-dibromo-4-(5-chloro-2-fluoro-3-[(methylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

25 3-(3,5-dibromo-4-{[3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid

3-[3,5-dibromo-4-(3-chloro-5-[(ethylsulfonyl)amino]benzyl)oxy]phenyl]propanoic acid

3-(3,5-dibromo-4-{[3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)-2-fluoropropanoic acid

30 3-[3,5-dibromo-4-(3-chloro-5-[(ethylsulfonyl)amino]benzyl)oxy]phenyl]-2-fluoropropanoic acid

- 3-[3,5-dibromo-4-($\{3\text{-[(ethylsulfonyl)amino]-5-methylbenzyl}\text{oxy}\}\text{phenyl}$)]-2-fluoropropanoic acid
- 3- $\{[3,5\text{-dibromo-4-(\{3-chloro-5-[(ethylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}]\text{amino}\}$ -3-oxopropanoic acid
- 5 3- $\{[3,5\text{-dibromo-4-(\{3-[(ethylsulfonyl)amino]-5-methylbenzyl}\text{oxy}\)\text{phenyl}]\text{amino}\}$ -3-oxopropanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(ethylsulfonyl)amino]-5-fluorobenzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3- $[3,5\text{-dibromo-4-(\{2-chloro-3-[(ethylsulfonyl)amino]benzyl}\text{oxy}\)\text{phenyl}}$]propanoic acid
- 3- $[3,5\text{-dibromo-4-(\{3-[(ethylsulfonyl)amino]-2-fluoro-5-methylbenzyl}\text{oxy}\)\text{phenyl}}$]
10 propanoic acid
- 3- $[3,5\text{-dibromo-4-(\{5-chloro-3-[(ethylsulfonyl)amino]-2-fluorobenzyl}\text{oxy}\)\text{phenyl}}$]propanoic acid
- 3- $[3,5\text{-dibromo-4-(\{3-[(methylsulfonyl)amino]benzyl}\text{oxy}\)\text{phenyl}}$]propanoic acid
- 3- $[3,5\text{-dibromo-4-(\{4-methyl-3-[(methylsulfonyl)amino]benzyl}\text{oxy}\)\text{phenyl}}$]propanoic
15 acid
- 3- $[3,5\text{-dibromo-4-(\{2-methyl-3-[(methylsulfonyl)amino]benzyl}\text{oxy}\)\text{phenyl}}$]propanoic acid
- 3-(3,5-dibromo-4- $\{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]\text{oxy}\}$)phenyl)
propanoic acid
- 20 3-[3,5-dibromo-4-($\{3\text{-methyl-5-[(methylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(ethylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-(3,5-dibromo-4- $\{[3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]\text{oxy}\}$)phenyl)
propanoic acid
- 25 3-[3,5-dibromo-4-($\{3\text{-[(ethylsulfonyl)amino]-2-methylbenzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(propylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(isopropylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(butylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 3-[3,5-dibromo-4-($\{3\text{-[(phenylsulfonyl)amino]benzyl}\text{oxy}\}\text{phenyl}$]propanoic acid
- 30 3-{3,5-dibromo-4-[(3- $\{[(3,5\text{-dimethylisoxazol-4-yl)sulfonyl]\text{amino}\}\text{benzyl}\}\text{oxy}\}$] phenyl }
propanoic acid

3-(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid

3-[3,5-dichloro-4-({3-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid

N-[3,5-dibromo-4-({3-[(methylsulfonyl)amino]benzyl}oxy)benzoyl]glycine

5 N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine

In particular:

3-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromophenyl)propanoic acid

3-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dichlorophenyl)propanoic acid

10 3-(4-{[3-(acetylamino)-4-methylbenzyl]oxy}-3,5-dibromophenyl)propanoic acid

3-(3,5-dibromo-4-{[3-(propionylamino)benzyl]oxy}phenyl)propanoic acid

3-(3,5-dichloro-4-{[3-(propionylamino)benzyl]oxy}phenyl)propanoic acid

3-(3,5-dibromo-4-{[3-(butyrylamino)benzyl]oxy}phenyl)propanoic acid

3-(3,5-dibromo-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid

15 3-(3,5-dichloro-4-{[3-(isobutyrylamino)benzyl]oxy}phenyl)propanoic acid

3-(3,5-dibromo-4-{[3-(isobutyrylamino)-2-methylbenzyl]oxy}phenyl)propanoic acid

3-[3,5-dibromo-4-({3-[(3-methylbutanoyl)amino]benzyl}oxy)phenyl]propanoic acid

3-[3,5-dibromo-4-({3-[(2E)-but-2-enoylamino]benzyl}oxy)phenyl]propanoic acid

3-[3,5-dibromo-4-({3-[(cyclopropylcarbonyl)amino]benzyl}oxy)phenyl]propanoic acid

20 3-[3,5-dibromo-4-({3-[(cyclobutylcarbonyl)amino]benzyl}oxy)phenyl]propanoic acid

3-[3,5-dibromo-4-({3-[(cyclopentylcarbonyl)amino]benzyl}oxy)phenyl]propanoic acid

N-(4-{[3-(acetylamino)benzyl]oxy}-3,5-dibromobenzoyl)glycine

N-(3,5-dibromo-4-{[3-(propionylamino)benzyl]oxy}benzoyl)glycine

N-(3,5-dibromo-4-{[3-(isobutyrylamino)benzyl]oxy}benzoyl)glycine

25

and

3-[3,5-dibromo-4-({3-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid

3-[3,5-dibromo-4-({4-methyl-3-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid

30 3-[3,5-dibromo-4-({2-methyl-3-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid

- 3-(3,5-dibromo-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
- 3-[3,5-dibromo-4-({3-methyl-5-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
- 5 3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-(3,5-dibromo-4-{[3-[(ethylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
- 3-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]-2-methylbenzyl}oxy)phenyl]propanoic acid
- 3-[3,5-dibromo-4-({3-[(propylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
- 10 3-[3,5-dibromo-4-({3-[(isopropylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-[3,5-dibromo-4-({3-[(butylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-[3,5-dibromo-4-({3-[(phenylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
3-{3,5-dibromo-4-[(3-{{(3,5-dimethylisoxazol-4-yl)sulfonyl}amino}benzyl)oxy]phenyl}propanoic acid
- 15 3-(3,5-dichloro-4-{[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)benzyl]oxy}phenyl)propanoic acid
3-[3,5-dichloro-4-({3-[(methylsulfonyl)amino]benzyl}oxy)phenyl]propanoic acid
N-[3,5-dibromo-4-({3-[(methylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
N-[3,5-dibromo-4-({3-[(ethylsulfonyl)amino]benzyl}oxy)benzoyl]glycine
- 20 The compounds names given above were generated in accordance with IUPAC by the ACD Labs/Name program, version 7.08 build 21.
- Salts and solvates of compounds of formula (I) which are suitable for use in medicine are those wherein a counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of the compounds of formula (I) and their pharmaceutically acceptable salts, solvates and physiologically functional derivatives.
- 25 By the term "physiologically functional derivative" is meant a chemical derivative of a compound of formula (I) having the same physiological function as the free compound of

formula (I), for example, by being convertible in the body thereto. According to the present invention, examples of physiological functional derivatives include esters, amides, and carbamates; preferably esters and amides.

- 5 Suitable salts according to the invention include those formed with organic or inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, acetic, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, perchloric, fumaric, maleic, glycollic, lactic, salicylic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, formic, 10 benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, and isethionic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutical acceptable acid addition salts. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts, for example those of potassium and sodium, alkaline earth metal salts, for example those of calcium and magnesium, and salts with organic bases, for 15 example dicyclohexylamine and N-methyl-D-glucamine.

- Pharmaceutically acceptable esters and amides of the compounds of formula (I) may have an appropriate group, for example an acid group, converted to a C₁₋₆ alkyl, C₅₋₁₀ aryl, 20 C₅₋₁₀ ar-C₁₋₆ alkyl, or amino acid ester or amide. Pharmaceutically acceptable amides and carbonates of the compounds of formula (I) may have an appropriate group, for example an amino group, converted to a C₁₋₆ alkyl, C₅₋₁₀ aryl, C₅₋₁₀ ar-C₁₋₆ alkyl, or amino acid ester or amide, or carbamate.
- 25 Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate".
- 30 A compound which, upon administration to the recipient, is capable of providing (directly or indirectly) compound of formula (I) as described above or an active metabolite or

residue thereof, is known as a "prodrug". A prodrug may, for example, be converted within the body, e. g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutical acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series; 5 and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

- 10 As used herein, the term "alkyl" means both straight and branched chain saturated hydrocarbon groups. Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, i-butyl, sec-butyl pentyl, hexyl, heptyl, octyl, nonyl and decyl groups. Among unbranched alkyl groups, there are preferred methyl, ethyl, n-propyl, iso-propyl, n-butyl groups. Among branched alkyl groups, there may be mentioned t-butyl, i-15 butyl, 1-ethylpropyl, 1-ethyl butyl and 1-ethylpentyl groups.

As used herein, the term "alkoxy" means the group O-alkyl, where "alkyl" is used as described above. Examples of alkoxy groups include methoxy and ethoxy groups. Other examples include propoxy and butoxy.

- 20 As used herein, the term "alkenyl" means both straight and branched chain unsaturated hydrocarbon groups with at least one carbon carbon double bond. Up to 5 carbon carbon double bonds may, for example, be present. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl and dodecenyl. 25 Preferred alkenyl groups includes ethenyl, 1- propenyl and 2- propenyl.

- As used herein, the term "alkynyl" means both straight and branched chain unsaturated hydrocarbon groups with at least one carbon carbon triple bond. Up to 5 carbon carbon triple bonds may, for example, be present. Examples of alkynyl groups include ethynyl, 30 propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and dodecynyl. Preferred alkenyl groups include ethynyl 1- propynyl and 2- propynyl.

As used herein, the term "cycloalkyl" means an aliphatic group in a ring system. The cycloalkyl group can be monocyclic or bicyclic. A bicyclic group may, for example, be fused or bridged. Examples of monocyclic cycloalkyl groups include cyclopropyl,
5 cyclobutyl and cyclopentyl. Other examples of monocyclic cycloalkyl groups are cyclohexyl, cycloheptyl and cyclooctyl. Examples of bicyclic cycloalkyl groups include bicyclo [2.2.1]hept-2-yl. Preferably, the cycloalkyl group is monocyclic.

As used herein, the term "aryl" means a monocyclic or bicyclic aromatic carbocyclic group. Examples of aryl groups include phenyl and naphthyl. A naphthyl group may be attached through the 1 or the 2 position. In a bicyclic aromatic group, one of the rings may, for example, be partially saturated. Examples of such groups include indanyl and tetrahydronaphthyl. A particularly preferred aryl group is phenyl.
10

15 As used herein, the term "halogen" means fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are particularly preferred.

As used herein, the term "heterocyclyl" means an aromatic ("heteroaryl") or a non-aromatic ("heterocycloalkyl") cyclic group of carbon atoms wherein from one to three of the carbon atoms is/are replaced by a heteroatom independently selected from nitrogen, oxygen or sulfur. A heterocyclyl group may, for example, be monocyclic or bicyclic. In a bicyclic heterocyclyl group there may be one or more heteroatoms in each ring, or only in one of the rings. The heteroatom is preferably O or N. Heterocyclyl groups include the corresponding N-oxides. Examples of heterocyclyl groups include piperidinyl,
20
25 tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrimidyl and indolyl.

As used herein the term "cycloalkylalkyl" means a group cycloalkyl-alkyl- attached through the alkyl group, "cycloalkyl" and "alkyl" being understood to have the meanings outlined above.

As mentioned above, the compounds of the invention have activity as thyroid receptor ligands. The compounds of the invention are preferably selective agonists or partial agonists of the thyroid receptor. Preferably compounds of the present invention possess activity as agonists of the thyroid receptor, preferably selective agonists of the thyroid receptor-beta. They may thus be used in the treatment of diseases or disorders associated with thyroid receptor activity, particularly diseases or disorders for which selective agonists of the thyroid receptor-beta are indicated. In particular, compounds of the present invention may be used in the treatment of diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T₃ regulated gene.

Clinical conditions for which an agonist or partial agonist is indicated include, but are not limited to, hypothyroidism; subclinical hyperthyroidism; non-toxic goiter; atherosclerosis; thyroid hormone replacement therapy (e.g., in the elderly); malignant tumor cells containing the thyroid receptor; papillary or follicular cancer; maintenance of muscle strength and function (e.g., in the elderly); reversal or prevention of frailty or age-related functional decline ("ARFD") in the elderly (e.g., sarcopenia); treatment of catabolic side effects of glucocorticoids; prevention and/or treatment of reduced bone mass, density or growth (e.g., osteoporosis and osteopenia); treatment of chronic fatigue syndrome (CFS); accelerating healing of complicated fractures (e.g. distraction osteogenesis); in joint replacement; eating disorders (e.g., anorexia); treatment of obesity and growth retardation associated with obesity; treatment of depression, nervousness, irritability and stress; treatment of reduced mental energy and low self-esteem (e.g., motivation/assertiveness); improvement of cognitive function (e.g., the treatment of dementia, including Alzheimer's disease and short term memory loss); treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction (e.g., associated with valvular disease, myocardial infarction, cardiac hypertrophy or congestive heart failure); lowering blood pressure; protection against ventricular dysfunction or prevention of reperfusion events; treatment of hyperinsulinemia; stimulation of osteoblasts, bone remodeling and cartilage growth; regulation of food intake; treatment of insulin resistance, including NIDDM, in mammals.

- (e.g., humans); treatment of insulin resistance in the heart; treatment of congestive heart failure; treatment of musculoskeletal impairment (e.g., in the elderly); improvement of the overall pulmonary function; skin disorders or diseases, such as dermal atrophy, glucocorticoid induced dermal atrophy, including restoration of dermal atrophy induced by topical glucocorticoids, and the prevention of dermal atrophy induced by topical glucocorticoids (such as the simultaneous treatment with topical glucocorticoid or a pharmacological product including both glucocorticoid and a compound of the invention), the restoration/prevention of dermal atrophy induced by systemic treatment with glucocorticoids, restoration/prevention of atrophy in the respiratory system induced by local treatment with glucocorticoids, UV-induced dermal atrophy, dermal atrophy induced by aging (wrinkles, etc.), wound healing, post surgical bruising caused by laser resurfacing, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen planus, ichthyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis and skin scarring. In addition, the conditions, diseases, and maladies collectively referenced to as "Syndrome X" or Metabolic Syndrome as detailed in Johannsson *J. Clin. Endocrinol. Metab.*, 82, 727-34 (1997), may be treated employing the compounds of the invention. The term treatment includes, where appropriate, prophylactic treatment.
- The compounds of the invention find particular application in the treatment or prophylaxis of the following: (1) hypercholesterolemia, dyslipidemia or any other lipid disorder manifested by an unbalance of blood or tissue lipid levels ; (2) atherosclerosis; (3) replacement therapy in elderly subjects with hypothyroidism who are at risk for cardiovascular complications; (4) replacement therapy in elderly subjects with subclinical hypothyroidism who are at risk for cardiovascular complications; (5) obesity; (6) diabetes (7) depression; (8) osteoporosis (especially in combination with a bone resorption inhibitor); (9) goiter; (10) thyroid cancer; (11) cardiovascular disease or congestive heart failure; (12) glaucoma; and (13) skin disorders.
- The compounds of the invention find especial application in the treatment or prophylaxis of the following: (1) hypercholesterolemia, dyslipidemia or any other lipid disorder

manifested by an unbalance of blood or tissue lipid levels ; (2) atherosclerosis; (3) obesity; (4) diabetes.

The invention also provides a method for the treatment or prophylaxis of a condition in a
5 mammal mediated by a thyroid receptor, which comprises administering to the mammal a therapeutically effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. Clinical conditions mediated by a thyroid receptor that may be treated by the method of the invention are
10 those described above.

The invention also provides the use of a compound of formula (I) as defined above or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for the manufacture of a
15 medicament for the treatment or prophylaxis of a condition mediated by a thyroid receptor. Clinical conditions mediated by a thyroid receptor that may be treated by the method of the invention are those described above.

20 Hereinafter, the term "active ingredient" means a compound of formula (I) as defined above, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt.

25 The amount of active ingredient which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, and the particular disorder or disease being treated. The compounds of the invention may be administered orally or via injection at a dose of from 0.1 to 1500 mg/kg per day, preferably 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 35 g per day and preferably 5 mg to 2 g per day. Tablets or other
30 forms of presentation provided in discrete units may conveniently contain an amount of

compound of the invention which is effective at such dosage or as a multiple of the same, for example units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.

While it is possible for the active ingredient to be administered alone, it is preferable for 5 it to be present in a pharmaceutical formulation. Accordingly, the invention provides a pharmaceutical formulation comprising a compound of formula (I) as defined above or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, and a pharmaceutically acceptable excipient.

10

The pharmaceutical formulations according to the invention include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered doses pressurized aerosols), nebulizers or 15 insufflators, rectal and topical (including dermal, buccal, sublingual, and intraocular) administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient.

The formulations may conveniently be presented in unit dosage form and may be 20 prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product 25 into the desired formulation.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an 30 aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-

in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or moulding, optionally with one or more
5 accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets
10 may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. The present compounds can, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the
15 case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds can also be administered liposomally.

Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate
20 as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The compounds of formula I can also be
25 delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses
30 (avicel) or polyethylene glycols (PEG). Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl

cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

5

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anit-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor.

10

15

20

25

Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline, which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

30

Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, synthetic glyceride esters or polyethylene glycol. Such carriers are typically solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.

Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia. Exemplary compositions for 5 topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

Preferred unit dosage formulations are those containing an effective dose, as hereinbefore 10 recited, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral 15 administration may include flavouring agents.

Whilst a compound of the invention may be used as the sole active ingredient in a medicament, it is also possible for the compound to be used in combination with one or more further active agents. Such further active agents may be further compounds 20 according to the invention, or they may be different therapeutic agents, for example an anti-dyslipidemic agent or other pharmaceutically active material.

The compounds of the present invention may be employed in combination with one or more other modulators and/or ligands of the thyroid receptor or one or more other 25 suitable therapeutic agents selected from the group consisting of cholesterol/lipid lowering agents, hypolipidemic agents, anti-atherosclerotic agents, anti-diabetic agents, anti-osteoporosis agents, anti-obesity agents, growth promoting agents, anti-inflammatory agents, anti-anxiety agents, anti-depressants, anti-hypertensive agents, cardiac glycosides, appetite suppressants, bone resorption inhibitors, thyroid mimetics, anabolic agents, anti- 30 tumor agents and retinoids..

Examples of suitable hypolipidemic agents for use in combination with the compounds of the present invention include an acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor, a microsomal triglyceride transfer protein (MTP) inhibitor, a cholesterol ester transfer protein (CETP) inhibitor, a ileal bile acid transporter (IBAT) inhibitor, any 5 cholesterol absorption inhibitor, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, a squalene synthetase inhibitor, a bile acid sequestrant, a peroxisome proliferator-activator receptor (PPAR)-alpha agonist, a peroxisome proliferator-activator receptor (PPAR)-delta agonist, any peroxisome proliferator-activator receptor (PPAR)-gamma/delta dual agonist, any peroxisome proliferator-activator receptor (PPAR)-alpha/delta dual agonist, a nicotinic acid or a derivative thereof, and a thiazolidinedione 10 or a derivative thereof.

Examples of suitable hypolipidemic agents for use in combination with the compounds of the present invention also include ezetimibe, simvastatin, atorvastatin, rosuvastatin, 15 cerivastatin, fluvastatin, lovastatin, pravastatin, fenofibrate, gemfibrozil and bezafibrate.

Examples of suitable anti-diabetic agents for use in combination with the compounds of the present invention include biguanides (e.g., metformin or phenformin), glucosidase inhibitors (e.g., acarbose or miglitol), insulins (including insulin secretagogues or insulin 20 sensitizers), meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, glipyride, gliclazide, chlorpropamide and glipizide), biguanide/glyburide combinations (e.g., Glucovance®), thiazolidinediones (e.g., troglitazone, rosiglitazone, englitazone, darglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR-alpha/gamma dual agonists, PPAR alpha/delta dual agonists, SGLT 1, 2 or 3 inhibitors, 25 glycogen phosphorylase inhibitors, inhibitors of fatty acid binding protein (aP2), glucagon-like peptide-1 (GLP-1), glucocorticoid (GR) antagonist and dipeptidyl peptidase IV (DP4) inhibitors.

Examples of suitable anti-osteoporosis agents for use in combination with the compounds 30 of the present invention include alendronate, risedronate, PTH, PTH fragment, raloxifene,

calcitonin, RANK ligand antagonists, calcium sensing receptor antagonists, TRAP inhibitors, selective estrogen receptor modulators (SERM) and AP-1 inhibitors.

Examples of suitable anti-obesity agents for use in combination with the compounds of
5 the present invention include aP2 inhibitors, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), a serotonin (and dopamine) reuptake inhibitor, such as
10 sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), other thyroid receptor beta drugs, such as a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and GB98/284425 (KaroBio), CB-1 (cannabinoid receptor) antagonists (see G. Colombo et al, "Appetite Suppression and Weight Loss After the Cannabionid Antagonist SR 141716", Life Sciences, Vol 63, PL 113-117
15 (1998)) and/or an anorectic agent, such as dexamphetamine, phentermine, phenylpropanolamine or mazindol.

The compounds of the present invention may be combined with growth promoting agents, such as, but not limited to, TRH, diethylstilbestrol, theophylline, enkephalins, E
20 series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeronol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.

The compounds of the invention may also be used in combination with growth hormone
25 secretagogues such as GHRP-6, GHRP-1 (as described in U.S. Patent No. 4,411,890 and publications WO 89/07110 and WO 89/07111), GHRP-2 (as described in WO 93/04081), NN703 (Novo Nordisk), LY444711 (Lilly), MK-677 (Merck), CP424391 (Pfizer) and B-HT920, or with growth hormone releasing factor and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2, or with alpha-adrenergic
30 agonists, such as clonidine or serotonin 5-HT_D agonists, such as sumatriptan, or agents which inhibit somatostatin or its release, such as physostigmine and pyridostigmine. A

still further use of the disclosed compounds of the invention is in combination with parathyroid hormone, PTH(1-34) or bisphosphonates, such as MK-217 (alendronate).

Examples of suitable anti-inflammatory agents for use in combination with the
5 compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, aspirin, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha-4 beta-7 integrin antagonists, 10 cell adhesion inhibitors, interferon gamma antagonists, ICAM-1, tumor necrosis factor (TNF) antagonists (e.g., infliximab, OR1384), prostaglandin synthesis inhibitors, budesonide, clofazimine, CNI-1493, CD4 antagonists (e.g., priliximab), p38 mitogen-activated protein kinase inhibitors, protein tyrosine kinase (PTK) inhibitors, IKK inhibitors, and therapies for the treatment of irritable bowel syndrome (e.g., Zelmac® and 15 Maxi-K® openers such as those disclosed in U.S. Patent No. 6,184,231 B1).

Example of suitable anti-anxiety agents for use in combination with the compounds of the present invention include diazepam, lorazepam, buspirone, oxazepam, and hydroxyzine pamoate.

20 Examples of suitable anti-depressants for use in combination with the compounds of the present invention include citalopram, fluoxetine, nefazodone, sertraline, and paroxetine.

Examples of suitable anti-hypertensive agents for use in combination with the compounds
25 of the present invention include beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g. diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynahen, chlorthalidone, furosemide, musolimine, 30 bumetanide, triamterene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril,

quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Patent Nos. 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase

5 inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates.

Examples of suitable cardiac glycosides for use in combination with the compounds of the present invention include digitalis and ouabain.

10 Examples of suitable cholesterol/lipid lowering agents for use in combination with the compounds of the present invention include HMG-CoA reductase inhibitors, squalene synthetase inhibitors, fibrates, bile acid sequestrants, ACAT inhibitors, MTP inhibitors, lipooxygenase inhibitors, an ileal Na^+ /bile acid cotransporter inhibitor, cholesterol absorption inhibitors, and cholesterol ester transfer protein inhibitors (e.g., CP-529414).

15 MTP inhibitors which may be employed herein in combination with one or more compounds of formula I include MTP inhibitors as disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Patent No.

20 5,962,440 all incorporated herein by reference.

The HMG CoA reductase inhibitors which may be employed in combination with one or more compounds of formula I include mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in

25 U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Further HMG CoA reductase inhibitors which may be employed herein include fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S.

30 Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610, indene analogs of

mevalonolactone derivatives, as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof, as disclosed in U.S. Patent No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone, as disclosed in PCT application 5 WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives, as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone, as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes, such as disclosed in U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin), as 10 disclosed in European Patent Application No. 0,142,146 A2, as well as other known HMG CoA reductase inhibitors.

The squalene synthetase inhibitors which may be used in combination with the compounds of the present invention include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. 15 Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinylmethyl)phosphonates, terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. 20 Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, as well as other squalene synthetase inhibitors as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, 25 M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

Bile acid sequestrants which may be used in combination with the compounds of the present invention include cholestyramine, colestipol and DEAE-Sephadex (Secholex®, 30 Policexide®), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphos-phorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku),

Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923,
5 quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

ACAT inhibitors suitable for use in combination with compounds of the invention include ACAT inhibitors as described in, Drugs of the Future 24, 9-15 (1999),

- 10 (Avasimibe); "The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc.
15 Drug Rev. (1998), 16(1), 16-30; "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways (1995), 173-
20 98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62.

30 Examples of suitable cholesterol absorption inhibitor for use in combination with the compounds of the invention include SCH48461 (Schering-Plough), as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

Examples of suitable ileal Na^+ /bile acid cotransporter inhibitors for use in combination with the compounds of the invention include compounds as disclosed in Drugs of the Future, 24, 425-430 (1999).

- 5 Examples of suitable thyroid mimetics for use in combination with the compounds of the present invention include thyrotropin, polythyroid, KB-130015, and dronedarone.

Examples of suitable anabolic agents for use in combination with the compounds of the present invention include testosterone, TRH diethylstilbestrol, estrogens, β -agonists, theophylline, anabolic steroids, dehydroepiandrosterone, enkephalins, E-series prostagladins, retinoic acid and compounds as disclosed in U.S. Pat. No. 3,239,345, e.g., Zeranol®; U.S. Patent No. 4,036,979, e.g., Sulbenox® or peptides as disclosed in U.S. Pat. No. 4,411,890.

- 15 For the treatment of skin disorders or diseases as described above, the compounds of the present invention may be used alone or optionally in combination with a retinoid, such as tretinoin, or a vitamin D analog.

A still further use of the compounds of the invention is in combination with estrogen, testosterone, a selective estrogen receptor modulator, such as tamoxifen or raloxifene, or other androgen receptor modulators, such as those disclosed in Edwards, J. P. et al., *Bio. Med. Chem. Let.*, 9, 1003-1008 (1999) and Hamann, L. G. et al., *J. Med. Chem.*, 42, 210-212 (1999).

- 25 A further use of the compounds of this invention is in combination with steroidal or non-steroidal progesterone receptor agonists ("PRA"), such as levonorgestrel, medroxyprogesterone acetate (MPA).

- 30 The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the

Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

Where the compounds of the invention are utilized in combination with one or more other
5 therapeutic agent(s), either concurrently or sequentially, the following combination ratios and dosage ranges are preferred:

When combined with a hypolipidemic agent, an antidepressant, a bone resorption inhibitor and/or an appetite suppressant, the compounds of formula I may be employed in
10 a weight ratio to the additional agent within the range from about 500:1 to about 0.005:1, preferably from about 300:1 to about 0.01:1.

Where the antidiabetic agent is a biguanide, the compounds of formula I may be employed in a weight ratio to biguanide within the range from about 0.01:1 to about 100:1,
15 preferably from about 0.5:1 to about 2:1.

The compounds of formula I may be employed in a weight ratio to a glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 50:1.

20 The compounds of formula I may be employed in a weight ratio to a sulfonylurea in the range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 10:1.

The compounds of formula I may be employed in a weight ratio to a thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to
25 about 5:1. The thiazolidinedione may be employed in amounts within the range from about 0.01 to about 2000 mg/day, which may optionally be administered in single or divided doses of one to four times per day. Further, where the sulfonylurea and thiazolidinedione are to be administered orally in an amount of less than about 150 mg, these additional agents may be incorporated into a combined single tablet with a
30 therapeutically effective amount of the compounds of formula I.

Metformin, or salt thereof, may be employed with the compounds of formula I in amounts within the range from about 500 to about 2000 mg per day, which may be administered in single or divided doses one to four times daily.

- 5 The compounds of formula I may be employed in a weight ratio to a PPAR-alpha agonist, a PPAR-gamma agonist, a PPAR-alpha/gamma dual agonist, an SGLT2 inhibitor and/or an aP2 inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 5:1..
- 10 An MTP inhibitor may be administered orally with the compounds of formula I in an amount within the range of from about 0.01 mg/kg to about 100 mg/kg and preferably from about 0.1 mg/kg to about 75 mg/kg, one to four times daily. A preferred oral dosage form, such as tablets or capsules, may contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, administered on a regimen of one to four times daily. For parenteral administration, the MTP inhibitor may be employed in an amount within the range of from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.005 mg/kg to about 8 mg/kg, administered on a regimen of one to four times daily.
- 15 A HMG CoA reductase inhibitor may be administered orally with the compounds of formula I within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg. A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 5 to about 80 mg, and more preferably from about 10 to about 40 mg.
- 20 A squalene synthetase inhibitor may be administered with the compounds of formula I within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg. A preferred oral dosage form, such as tablets or capsules, will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.
- 25
- 30


The compounds of formula (I) as described above also find use, optionally in labelled form, as a diagnostic agent for the diagnosis of conditions associated with malfunction of the thyroid receptor. For example, such a compound may be radioactively labelled.

5

The compounds of formula (I) as described above, optionally in labelled form, also find use as a reference compound in methods of discovering other antagonists or partial antagonists of the thyroid receptor. For example, such a method may involve a competitive binding experiment in which binding of a compound of formula (I) to the thyroid receptor is reduced by the presence of a further compound which has thyroid receptor-binding characteristics, for example stronger thyroid receptor-binding characteristics than the compound of formula (I) in question.

10

15 The invention also provides a method for preparing a compound in of formula (I) accordance with the invention as described above comprising a step of reacting - a compound of formula (II)



20

wherein R², n, Y', Y, R³, R⁴, W and R⁵ are as defined above

- with a compound of formula R¹-L, wherein R¹ is as defined above and L is a suitable leaving group, optionally in the presence of a suitable base, followed optionally by interconversion to another compound in accordance with the invention.

Suitable leaving groups L include halogen, OR^c , $-\text{SR}^c$, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{5-10}\text{aryl}$ or $\text{C}_{5-10}\text{ar-C}_{1-4}\text{alkyl}$ sulphonate esters, for example, a bromide, a methylsulfonyl or a toluenesulfonyl group. Particularly preferred compounds $\text{R}^1\text{-L}$ are acid chlorides (R^6COCl) and 5 sulphonylchlorides ($\text{R}^6\text{SO}_2\text{Cl}$) ie reagents in which the leaving group L is Cl. Suitable bases include carbonates, alkylamines and alkali metal hydroxides, for example potassium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide diisopropylamine and, triethylamine. Trimethylsilanoate may also be used. Other combinations of leaving groups and bases may be employed, as is known by the person skilled in the art. Optionally, one or more coupling reagents may be employed. The 10 reaction mixture is stirred at room temperature, or heated until the starting materials have been consumed. The reaction may be carried out with protecting groups present and those protecting groups may be removed after the reaction. Suitable protecting groups are known to the person skilled in the art (see T. W. Greene, "Protective Groups in 15 Organic Synthesis", 3rd Edition, New York, 1999).

The invention will now be illustrated by the following Examples, which do not in any way limit the scope of the invention.

20 Examples

The following compounds illustrate compounds of the invention or, where appropriate, compounds for use in the invention.

Methyl 3-(4-hydroxy-3,5-dibromophenyl) propionate

25 To a solution of 3-(4-hydroxyphenyl) propionate methyl ester (10 g, 55.5 mmol) in acetic acid (150 mL), bromine (19.5 g, 121.9 mmol) was added drop wise slowly. The reaction mixture was stirred for 5h at room temperature and then evaporated and co-evaporated with ethyl acetate (2x200 mL). The residue was purified on silica gel column to give 17.0 g of the title compound (90.6% yield).

30

Methyl 3-(4-hydroxy-3,5-dichlorophenyl) propionate

Methyl-3-(4-hydroxyphenyl) propionate (35.6 g, 0.198 mol) was dissolved in dichloromethane (200 mL). The reaction mixture was cooled to 4°C and sulfonyl chloride (120 mL, 1.42 mol) in diethyl ether (200 mL) was added drop wise to the reaction mixture over 1 h. After 3h at room temperature the solvent was removed. The reaction
5 mixture was dissolved in dichloromethane and washed with water. The combined organic phases were dried over sodium sulphate, filtered and evaporated. The product was purified by flash chromatography (diethyl ether/heptane) to provide 16.6 g (34%) of the title compound.

10 **Methyl (3,5-dibromo-4-hydroxy-benzoylamino) acetate**

3,5-Dibromo-4-hydroxybenzoic acid (5.1 g, 17.23 mmol) was refluxed in thionyl chloride (100 mL) for 6h. The reaction mixture was cooled and the excess thionyl chloride removed. The product was used in the next step without further purification.
Glycine methyl ester hydrochloride (4.33 g, 34.5 mmol) was dissolved in
15 dichloromethane (430 mL) and triethyl amine (20 mL, 143.6 mmol). The acid chloride (17.23 mmol) was added in small portions. Stirring was continued overnight. The solvent was evaporated. The reaction mixture was dissolved in dichloromethane and washed with 0.1 M HCl aqueous solution. The organic phase was dried over sodium sulphate, filtered and the solvent removed. A small amount of ethyl acetate was added and the mixture was
20 filtered to give 4.21 g (88%) of almost pure compound. The product was crystallized from heptanes/ethyl acetate to give 2.5 g of the title compound (52% yield) as a white powder.

25 **5-Trifluoromethyl-3-nitrobenzylbromide**

5-Trifluoromethyl-3-nitrobenzoic acid (0.7g, 3.0 mmol) was dissolved in methanol and 10 drops of H₂SO₄ (conc.) was added, and the reaction was stirred over night at reflux temperature. Methanol was removed and the residue re-dissolved in CH₂Cl₂ and washed with water. The solvent was dried (MgSO₄) and removed under vacuum to give 0.71 g of 5-trifluoromethyl-3-nitrobenzoate methyl ester.

To lithium aluminium hydride (0.32 g, 8.7 mmol) in THF (8 mL) was carefully, and drop wise, added a solution of 5-trifluoromethyl-3-nitrobenzoate methyl ester in THF (2 mL) and stirred at room temperature over night. The reaction was quenched with careful addition of water (20 mL) then acidified using 3 M HCl and finally extracted with diethylether (3 x 50mL). The combined organic phases were dried (MgSO_4) and the solvent was removed under vacuum. The residue was purified on silica gel column ($\text{Et}_2\text{O}/\text{heptane}$ 1:3) to provide 0.35g, (55%) of 5-trifluoromethyl-3-nitrobenzylalcohol. 5-Trifluoromethyl-3-nitrobenzylalcohol was dissolved in 3 mL toluene and 0.1mL PBr_3 was added with a syringe and the reaction was stirred at room temperature over night. The reaction was filtered throw a plug of silica which was washed with Et_2O . The solvent was removed under vacuum to give 0.38 g (85% yield) of the title compound.

5-Methyl-3-nitrobenzylbromide

5-Methyl-3-nitrotoluene (0.5 g, 3.3 mmol) and NBS (0.6 g, 3.3 mmol) were dissolved in CCl_4 and benzoylperoxide (10 mg) was added. The reaction was refluxed over night and then cooled to room temperature. The reaction mixture was filtered and the solvent evaporated after which the residue was dissolved in CH_2Cl_2 and filtered throw a plug of silica. The obtained residue was a 2:1 mixture of the corresponding 5-methyl-3-nitrobenzylbromide and starting material. The yield was calculated to 65%.

5-Chloro-3-nitrobenzylbromide

5-Chloro-3-nitrotoluene (synthesized following *Journal of Medicinal Chemistry*, 2000, 43, 4733) (0.33g, 1.9 mmol) and NBS (0.34 g, 1.9 mmol) were dissolved in 9 mL of CCl_4 and 10 mg of benzoylperoxide were added. The reaction was refluxed over night and the cooled to room temperature. The reaction mixture was filtered and the solvent evaporated after which the residue was dissolved in CH_2Cl_2 and was filtered throw a plug of silica. The solvent was again evaporated to give 0.55 g crude product containing staring material the monobrominated and the dibrominated benzyl compound. Purification on silica ($\text{Et}_2\text{O}/\text{heptane}$ 9:1) gave 0.13 g (27% yield) of 5-chloro-3-nitrobenzylbromide.

**GENERAL PROCEDURE FOR THE PREPARATION OF THE ANILINES OF
5 THE INVENTION**

A mixture of the appropriate phenol (e.g. methyl 3-[3,5-dihalo-4-hydroxyphenyl] propionate) (1 eq.), the appropriate 3-nitrobenzylbromide (1 eq.) and potassium carbonate (5 eq.) in dry acetone (30 mL/mmol phenol) was heated to 56°C and stirred for 20 h. The reaction mixture was concentrated, diluted with EtOAc and washed with water. The 10 organic phase was dried, evaporated and purified on a column (silica, 100% dichloromethane) to give the nitro derivative (e.g. methyl 3-[3,5-dihalo-4-(3-nitrobenzyloxy)phenyl] propionate).

A mixture of the nitro derivative (e.g. methyl 3-[3,5-dihalo-4-(3-nitrobenzyloxy)phenyl] propionate) and tin(II)chloride dihydrate (5 eq.) in absolute ethanol (40 mL/mmol ester) 15 was heated to 75°C for 4h. The reaction mixture was quenched with sodium hydrogen carbonate aqueous solution (saturated). The aqueous phase was extracted with ethyl acetate (3x40 mL) and the combined organic phases were washed with water and brine and dried over magnesium sulphate. After evaporation of the solvent, the residue was 20 purified by flash chromatography (dichloromethane/diethylether 90:10) to yield the wanted amino derivative (e.g. methyl 3-[(3,5-dihalo-4-(3-aminobenzyloxy)phenyl] propionate).

Amides -

25 **GENERAL PROCEDURE FOR THE PREPARATION OF EXAMPLES 1-17**

METHOD A1

The appropriate acid chloride (R_6COCl) (2 eq.) was added to a dichloromethane solution of the appropriate aniline (e.g. methyl 3-[3,5-dihalo-4-(3-aminobenzyloxy)phenyl] 30 propionate) (1 eq.) and triethylamine (1.5 eq.). The mixture was stirred at room temperature for 1-3 h. Water was added and the mixture was acidified with HCl (1M) and

extracted with dichloromethane (3x25 mL). The organic phases were combined, the solvent was removed *in vacuo* and the residue was purified by flash chromatography to provide the desired amide (e.g. methyl 3-[3,5-dihalo-4-(3-acetylamino-benzyloxy)phenyl] propionate).

5

The amide (e.g. methyl 3-[3,5-dihalo-4-(3-acetylamino-benzyloxy)phenyl] propionate) was dissolved in dioxane (7 mL/mmol ester), sodium hydroxide (LiOH has also been used) (1 N in water, 5 eq.) was added and the mixture was stirred at room temperature over night. After acidification with hydrochloric acid (1 M) the product was extracted into ethyl acetate. The solvent was evaporated under vacuum to give the wanted acid (e.g. 3-[3,5-dihalo-4-(3-acetylamino-benzyloxy)phenyl] propionic acid).

10

METHOD A2

The appropriate acid chloride (R_6COCl) (1 eq) was dissolved in dichloromethane (2.5 mL/mmol), and added to a solution of the appropriate aniline (e.g. methyl 3-[3,5-dihalo-4-(3-acetylamino-benzyloxy)phenyl] propionate) (1 eq) in THF (16 mL/mmol) containing Polystyrene bound diisopropylethyl amine (3.83 mmol/g, 6 eq). The mixtures were stirred over night at 50°C.


20

The resin was filtered off, and the dichloromethane /THF solution was run through a short silica based amine column (Isolute, 1g, 0.6 mmol/g) to remove unreacted acid chloride. The column was rinsed with DCM (2 ml), and the combined eluates were evaporated. The material was dissolved in THF (0.5 ml) and LiOH (1M, 1 ml) was added. The mixture was stirred over night at room temperature.

25

The reaction mixture was separated by semi-preparative-HPLC (Zorbax CombiHT (SB-C8 50x21.2 mm, 5 μ) Mobile Phase: Solvent A: Water with 0.5% formic acid; Solvent B: acetonitrile. Gradient: 20-100% acetonitrile gradient). Appropriate fractions were combined and evaporated to give the expected acid (e.g. 3-[3,5-dihalo-4-(3-acetylamino-benzyloxy)phenyl] propionic acid).

30




Example	R ₆	R ₂	X	Yield (%)	MW (calc)	M ⁺ +1 (found)*	Method
1	Me	H	Br	37	471.1	470.6 (M ⁺ -1)	A1
2	Me	H	Cl	18	382.2	380.0 (M ⁺ -2)	A2
3	Me	4-Me	Br	10	485.1	486.5	A2
4	Et	H	Br	85.1	485.2	486.0	A2
5	Et	H	Cl	17	396.2	394.3 (M ⁺ -2)	A2
6	n-Pr	H	Br	21.5	499.2	500.0	A2
7	i-Pr	H	Br	56	499.0	500.0	A1
8	i-Pr	H	Cl	40	410.2	410.1 (M ⁺)	A2
9	i-Pr	2-Me	Br	52	513.2	514.1	A2
10	i-Bu	H	Br	29.2	513.2	514.0	A2
11	i-Propenyl	H	Br	17.2	497.2	498.0	A2
12	Cyclopropyl	H	Br	18	497.2	498.0	A2
13	Cyclobutyl	H	Br	50.1	511.2	512.0	A2
14	Cyclopentyl	H	Br	45.2	525.2	526.0	A2

*-Analyzed on HPLC-MS with alternating +/- API and equipped with different brands of

5 50 mm*2.1mm, 5μ C8 columns. Eluted with 0.05% formic acid/ACN or 0.05% ammonium acetate/ACN

*MW calc. (molecular weight) is an isotopic average and the "found mass" is referring to the most abundant isotope detected in the LC-MS.



Example	R ₆	R ₂	X	Yield (%)	MW (calc)	M ⁺ +1 (found)*	Method
15	Me	H	Br	20	500.1	501.0	A2
16	Et	H	Br	20	514.1	515.0 (M ⁺ -1)	A2
17	i-Pr	H	Br	16	528.2	529.0 (M ⁺ -1)	A2

*-Analyzed on HPLC-MS with alternating +/- API and equipped with different brands of

5 50 mm*2.1mm, 5μ C8 columns. Eluted with 0.05% formic acid/ACN or 0.05% ammonium acetate/ACN

*MW calc. (molecular weight) is an isotopic average and the "found mass" is referring to the most abundant isotope detected in the LC-MS.

10

Sulphonamides-

GENERAL PROCEDURE FOR THE PREPARATION OF EXAMPLES 18-35

METHOD B1

- 15 The dichloromethane solution of the appropriate aniline (e.g. methyl 3-(3,5-dihalo-4-(3-aminobenzyloxy)phenyl) propionate) (1 eq.) was treated with the appropriate sulphonylchloride (R₆SO₂Cl) (4 eq.) and pyridine (2.5 eq.). The mixture was stirred at 40°C for 2 h. Water was added and the mixture was acidified with HCl (1M) and extracted with dichloromethane (3x25 mL). The organic phases were combined, the solvent was removed under vacuum and the residue was purified by flash
- 20


chromatography to provide the desired the sulphonamide (e.g. methyl 3-[3,5-dihalo-4-(3-methanesulfonylamino-benzyloxy)phenyl] propionate).

The sulphonamide (e.g. methyl 3-[3,5-dihalo-4-(3-methanesulfonylamino-benzyloxy)phenyl] propionate) was dissolved in dioxane (7 mL/mmol ester), sodium hydroxide (LiOH has also been used) (1 N in water, 5 eq.) was added and the mixture was stirred at room temperature over night. After acidification with hydrochloric acid (1 N) the product was extracted into ethyl acetate. The solvent was evaporated under vacuum to yield the corresponding acid (e.g. 3-[3,5-dihalo-4-(3-methanesulfonylamino-benzyloxy)phenyl] propionic acid).

METHOD B2

The dichloromethane solution of the appropriate aniline (e.g. methyl 3-[3,5-dihalo-4-(3-methanesulfonylamino-benzyloxy)phenyl] propionate) (1 eq.) was treated with the appropriate sulphonylchloride (R_6SO_2Cl) (3 eq.) and pyridine (2.5 eq.). The mixture was stirred at 40 C for 4 h. The solvent was removed under vacuo and the residue was used in the next reaction without further purification.

The crude mixture was dissolved in THF (6 mL/mmol ester), lithium hydroxide (1 N in water, 10 eq.) was added and the mixture was stirred at room temperature over night. The reaction mixture was acidified to pH=5 with HCl (3 N). After filtration, the residue was purified by semi-preparative-HPLC (Zorbax CombiHT (SB-C8 50x21.2 mm, 5 μ) Mobile Phase: Solvent A. Water with 0.5% formic acid; Solvent B: acetonitrile. Gradient: 2 min 80% of A then over 8 min to 5% of A) to give the expected acid (e.g. 3-[3,5-dihalo-4-(3-methanesulfonylamino-benzyloxy)phenyl] propionic acid).




Example	R ₆	R ₂	X	Yield (%)	MW (calc)	M ⁺ -1 (found)*	Method
18	Me	H	Br	75	507.2	508.1 (M ⁺ +1)	B1
19	Me	4-Me	Br	18	521.2	520.4	B2
20	Me	2-Me	Br	46	521.2	520.4	B1
21	Me	5-CF ₃	Br	37	575.2	574.4	B1
22	Me	5-Me	Br	59	521.2	520.4	B2
23	Et	H	Br	41	521.2	520.1	B2
24	Et	2-Me	Br	49	535.3	534.2	B2
25	Et	5-CF ₃	Br	75	589.2	587.9	B2
26	n-Pr	H	Br	57	535.2	534.2	B2
27	i-Pr	H	Br	10	535.2	534.2	B2
28	n-Bu	H	Br	53	549.3	548.3	B2
29	Ph	H	Br	42	569.2	568.1	B2
30	2,5-Methyl-isoxazolyl	H	Br	52	588.2	587.1	B2
31	Me	H	Cl	67	418.3	416.6 (M ⁺ -2)	B2
32	Et	H	Cl	73	432.3	430.1 (M ⁺ -2)	B2
33	Me	5-CF ₃	Cl	37	486.3	484.4 (M ⁺ -2)	B2

*-Analyzed on HPLC-MS with alternating +/- API and equipped with different brands of 50 mm*2.1mm, 5μ C8 columns. Eluted with 0.05% formic acid/ACN or 0.05%

5 ammonium acetate/ACN

*MW calc. (molecular weight) is an isotopic average and the "found mass" is referring to the most abundant isotope detected in the LC-MS.



Example	R ₆	R ₂	X	Yield (%)	MW (calc)	M ⁺ +1 (found)*	Method
34	Me	H	Br	52	536.2	535.1 (M ⁺ -1)	B2
35	Et	H	Br	62	550.2	549.5 (M ⁺ -1)	B2

5 *-Analyzed on HPLC-MS with alternating +/- API and equipped with different brands of 50 mm*2.1mm, 5μ C8 columns. Eluted with 0.05% formic acid/ACN or 0.05% ammonium acetate/ACN

*MW calc. (molecular weight) is an isotopic average and the "found mass" is referring to the most abundant isotope detected in the LC-MS.

10

Abbreviations:

THF: Tetrahydrofuran

NBS: N-Bromosuccinimide

DCM: Dichloromethane

15 ACN: acetonitrile

Biological Assays

The utility of the compounds of the present invention can be evidenced by activity in at least one of the assays below.

20

1. Binding to thyroid hormone receptors

The ability of compounds of the present invention to bind to thyroid hormone receptors was demonstrated and evaluated by the present inventors using a selection of the protocols found in the following scientific literature:

5

- 1) Barkhem, T.; Carlsson, B.; Simons, J.; Moeller, B.; Berkenstam, A.; Gustafsson, J.-Å.; Nilsson, S. High level expression of functional full-length human thyroid hormone receptor β 1 in insect cells using a recombinant baculovirus. *J. Steroid Biochem. Mol. Biol.*, **1991**, *38*, 667-75.

10

- 2) Carlsson, B.; Singh, B. N.; Temciuc, M.; Nilsson, S.; Li, Y.-L.; Mellin, C.; Malm, J. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. *J. Med. Chem.*, **2002**, *45*, 623-630.

15

- 3) Liu Ye, Yi-Lin Li, Karin Mellström, Charlotta Mellin, Lars-Göran Bladh, Konrad Koehler, Neeraj Garg, Ana Maria Garcia Collazo, Chris Litten, Bolette Husman, Karina Persson, Jan Ljunggren, Gary Grover, Paul G. Slep, Rocco George, Johan Malm: Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β 1. *J. Med. Chem.*, **2003**, *45*, 1580-1588.

20

The literature above contain not only protocols for binding experiments to the TR-receptor, but also vector constructs, generation of reporter cell lines and the corresponding assay procedures.

25

Compounds of the invention were found to exhibit binding affinities to the TR receptor in the range of from 1 nM to 500 nM.

2. Lipid lowering effects in cholesterol fed rats

- 30 The ability of a compound of the present invention to lower lipid levels in animals can be demonstrated and evaluated by those skilled in the art, using the following protocols:

Cholesterol fed C57BL/6J mice

Weanling C57BL/6J mice are placed on a special diet protocol (Purina chow supplemented with 1.5% cholesterol, 15% saturated fat and 0.5% cholic acid) for two weeks before administration of drugs. The animals are housed at room temperature, 12:12 light dark cycle, and free access to food and water. On the day of treatment all animals are weighed before drug was administrated by intraperitoneal injection or by gavage. Compounds are administrated once daily for 5-10 days, at different concentrations (nmol/kg body weight), in suitable vehicle. On the last day of treatment, food is removed from the cages and the animals are fasted for at least 4 hours before termination of the study. Blood for serum or plasma is collected, and different organs are dissected and immediately frozen for later analyses. Blood and tissue lipid analyses are consecutively executed using commercial and readily available kits for the determination.

15 Ob/ob mice

The value of ob/ob mouse is well documented and appreciated by the one skilled in the art for monitoring "Metabolic Syndrome X".

6-8 weeks old female ob/ob mice (i.e. leptin deficient mice) purchased from commercial supplier were used to characterize compounds binding to thyroid hormone receptors alpha (TR α) and beta (TR β). The animals were weighed and randomly divided into different study groups, and kept for a minimum of 5 days to adapt to the new environment (animal facility). The animals were housed at room temperature, 12:12 light dark cycle, and free access to food and water. On the day of treatment all animals were weighed before drug was administrated by intraperitoneal injection or by gavage. Compounds were administrated once daily for 5-10 days, at different concentrations (nmol/kg body weight), in suitable vehicle. On the last day of treatment, food was removed from the cages and the animals were fasted for at least 4 hours before termination of the study. Blood for serum or plasma was collected, and different organs are dissected and immediately frozen for later analyses. Blood and tissue lipid analyses


were consecutively executed using commercial and readily available kits for the determination.

Other assays that may be used for the demonstration of the effectiveness of the
5 compounds of the invention include those described in the following references:

- 1) Liu Ye, Yi-Lin Li, Karin Mellström, Charlotta Mellin, Lars-Göran Bladh, Konrad Koehler, Neeraj Garg, Ana Maria Garcia Collazo, Chris Litten, Bolette Husman, Karina Persson, Jan Ljunggren, Gary Grover, Paul G. Slep, Rocco George, Johan Malm: Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β_1 . *J. Med. Chem.*, **2003**, *45*, 1580-1588.
 - 2) Liu Ye, Johan Malm, Yi-Lin Li, Lars-Göran Bladh, Karin Mellström, Paul G. Slep, Mark A. Smith, Rocco George, Björn Vennström, Kasim Mookhtiar, Ryan Horvath, Jessica Speelman, John D. Baxter, Gary J. Grover: Selective Thyroid Hormone Receptor- β Activation: A Strategy for Reduction of Weight, Cholesterol, and Lp(a) with Reduced Cardiovascular Liability. *PNAS*, **2003**, *100*, 10067-10072.
- 10
15
20 Other assays to determine thyroid receptor mediated activity of the test compounds include assays that demonstrate modulation of endogenous TR mediated transcription in cell culture systems; assays that demonstrate modulation of thyroid responsive tissue effects in rodents; assays for the identification of receptor surface conformation changes; and assays that demonstrate binding specificity to TR versus other nuclear receptors.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester,
 5 amide or salt,



10

wherein:

R^1 is selected from $-SO_2R^6$, $-SOR^6$ and $-C(O)R^6$;

R^6 is selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl-
 15 C_{1-3} alkyl, C_{5-7} aryl and C_{1-7} heterocyclyl, said alkyl, alkenyl or alkynyl optionally being
 substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, methoxy
 or methoxy substituted with 1 to 3 halogen atoms; said cycloalkyl, aryl or heterocyclyl
 optionally being substituted with 1, 2 or 3 groups independently selected from halogen,
 hydroxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, methoxy, or methoxy or C_{1-4} alkyl
 20 substituted with 1 to 3 halogen atoms;

Each R^2 is independently selected from halogen, mercapto, nitro, cyano, alkoxy, $-CO_2R^c$,
 $-CONHR^c$, $-CHO$, $-SO_2R^6$, $-SO_2NHR^6$, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, NHR^1 and
 $NH(R^1)_2$, said alkyl, alkenyl, alkynyl or alkoxy optionally being substituted with 1, 2 or 3
 25 groups selected from halogen, hydroxy, methoxy, C_{1-4} alkoxy, C_{1-4} alkylthio, mercapto,
 nitro, cyano or methoxy substituted with 1 to 3 halogen atoms;

n is 0, 1, 2 or 3;

Y and Y' are independently selected from oxygen, sulphur or -CH(R^a)-, with the proviso
5 that at least one of Y and Y' is -CH(R^a)- and the further proviso that when one of Y and
Y' is oxygen or sulphur, then R^a is hydrogen, halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄
alkynyl, fluoromethyl, difluoromethyl, trifluoromethyl;

10 R^a is selected from hydrogen, halogen, hydroxy, mercapto, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄
alkynyl, C₁₋₄ alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,
difluoromethoxy or trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio
or thiotrifluoromethyl;

15 R³ and R⁴ are independently selected from halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,
fluoromethyl, difluoromethyl, trifluoromethyl, C₁₋₄ alkoxy, fluoromethoxy,
difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio or
trifluoromethylthio;

20 W is selected from C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, N(R^b)-C₁₋₃ alkylene,
C(O)-C₁₋₃ alkylene, S-C₁₋₃ alkylene, O-C₁₋₃ alkylene, C(O)NH-C₁₋₃ alkylene or NH(CO)-
C₀₋₃ alkylene, said alkylene, alkenylene or alkynylene optionally being substituted with 1
or 2 groups selected from hydroxy, mercapto, amino, halo, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃
alkyl substituted with 1, 2 or 3 halogen atoms, and C₁₋₃ alkoxy substituted with 1, 2 or 3
halogen atoms;


25 R^b is selected from hydrogen, hydroxy, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy,
fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy,
trifluoromethoxy;

30 R⁵ is selected from -CO₂R^c, -PO(OR^c)₂, -PO(OR^c)NH₂, -SO₂OR^c, -COCO₂R^c,
CONR^cOR^c, -SO₂NHR^c, -NHSO₂R^c, -CONHSO₂R^c, and - SO₂NHCOR^c;

Each R^c is independently selected from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl and C₂₋₄ alkynyl;

5 R^{c'} is selected from R^c, C₅₋₁₀ aryl and C₅₋₁₀ aryl substituted with amino, hydroxy, halogen or C₁₋₄ alkyl.

2. A compound as claimed in claim 1 which is a compound according to formula (Ia) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such
10 an ester or amide, and a solvate of such an ester, amide or salt,



15 wherein:

R¹ is selected from -SO₂R⁶ and -C(O)R⁶;

R⁶ is selected from C₁₋₈ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, C₆ aryl and C₃₋₇ heterocyclyl, said alkyl or alkenyl optionally being substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, methoxy or halomethoxy; said cycloalkyl, aryl or heterocyclyl optionally being substituted with 1, 2 or 3 groups independently selected from halogen, methyl, methoxy, or methoxy substituted with 1 to 3 halogen atoms;

25 Each R² is independently selected from halogen, C₁₋₂ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl C₁₋₂ alkoxy and C₁₋₂ alkyl substituted with 1, 2 or 3 halogen atoms;

n is 0, 1 or 2;

Y is O or S, and Y' is CH(R^a);

5

R^a is preferably selected from hydrogen, halogen, C₁₋₂ alkyl, fluoromethyl, difluoromethyl and trifluoromethyl;

10 R³ and R⁴ are independently selected from halogen, C₁₋₄ alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C₁₋₄ alkoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio or trifluoromethylthio;

15 W is selected from C₁₋₃ alkylene, C(O)-C₁₋₂ alkylene, C(O)NH-C₁₋₂ alkylene or NH(CO)-C₁₋₂ alkylene;

20 R⁵ is selected from -CO₂R^c, -PO(OR^c)₂, -SO₂OR^c, -COCO₂R^c, CONR^cOR^c and -NHSO₂R^{c'};

25 Each R^c is independently selected from hydrogen and C₁₋₄ alkyl; and

R^{c'} is selected from R^c, phenyl and phenyl substituted with amino, hydroxyl, halogen or methyl.

25 3. A compound as claimed in claim 1 or claim 2 for use as a medicament.

4. A compound as claimed in claim 3 for use in the treatment or prophylaxis of a condition associated with a disease or disorder associated with thyroid receptor activity.

30 5. A method for the treatment or prophylaxis of a disease or disorder associated with thyroid receptor activity in a mammal, which comprises administering to the mammal a

therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt.

5 6. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for the manufacture of a medicament for the treatment or prophylaxis of a condition associated with a disease or disorder associated with thyroid receptor activity.

10

7. A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, and a pharmaceutically acceptable excipient.

15

8. A pharmaceutical formulation as claimed in claim 7 further comprising an additional therapeutic agent selected from cholesterol/lipid lowering agents, hypolipidemic agents, anti-atherosclerotic agents, anti-diabetic agents, anti-osteoporosis agents, anti-obesity agents, growth promoting agents, anti-inflammatory agents, anti-anxiety agents, anti-depressants, anti-hypertensive agents, cardiac glycosides, appetite suppressants, bone resorption inhibitors, thyroid mimetics, anabolic agents, anti-tumor agents and retinoids.

20 9. Use of a compound as defined in claim 1 in labelled form as a diagnostic agent for the diagnosis of conditions associated with a disease or disorder associated with thyroid receptor activity.

25 10. Use of a compound as defined in claim 1 or a labelled form of such a compound as a reference compound in a method of identifying ligands for the thyroid hormone receptor.


30 11. A compound as claimed in claim 4, a method as claimed in claim 5, a use as claimed in claim 6 or claim 9, or a pharmaceutical formulation as claimed in claim 7 or claim 8

wherein the condition associated with a disease or disorder associated with thyroid receptor activity is selected from (1) hypercholesterolemia, dyslipidemia or any other lipid disorder manifested by an unbalance of blood or tissue lipid levels ; (2) atherosclerosis; (3) replacement therapy in elderly subjects with hypothyroidism who are 5 at risk for cardiovascular complications; (4) replacement therapy in elderly subjects with subclinical hypothyroidism who are at risk for cardiovascular complications; (5) obesity; (6) diabetes (7) depression; (8) osteoporosis (especially in combination with a bone resorption inhibitor); (9) goiter; (10) thyroid cancer; (11) cardiovascular disease or congestive heart failure; (12) glaucoma; and (13) skin disorders.

10

12. A method for preparing a compound of formula (I) as described in claim 1 comprising a step of reacting
- a compound of formula (II)

15



wherein R^2 , n, Y' , Y, R^3 , R^4 , W and R^5 are as defined in claim 1

20

- with a compound of formula R^1-L , wherein R^1 is as defined in claim 1 and L is a suitable leaving group, optionally in the presence of a suitable base, followed optionally by interconversion to another compound as described in claim 1.

25

13. A pharmaceutical composition as claimed in claim 8 wherein the additional therapeutic agent is a hypolipidemic agent selected from the group consisting of an acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor, a microsomal triglyceride

- transfer protein (MTP) inhibitor, a cholesterol ester transfer protein (CETP) inhibitor, a ileal bile acid transporter (IBAT) inhibitor, any cholesterol absorption inhibitor, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, a squalene synthetase inhibitor, a bile acid sequestrant, a peroxisome proliferator-activator receptor 5 (PPAR)-alpha agonist, a peroxisome proliferator-activator receptor (PPAR)-delta agonist, any peroxisome proliferator-activator receptor (PPAR)-gamma/delta dual agonist, any peroxisome proliferator-activator receptor (PPAR)-alpha/delta dual agonist, a nicotinic acid or a derivative thereof, and a thiazolidinedione or a derivative thereof.
- 10 14. A pharmaceutical composition as claimed in claim 8 wherein the additional therapeutic agent is a hypolipidemic agent selected from the group consisting of ezetimibe, simvastatin, atorvastatin, rosuvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, fenofibrate, gemfibrozil and bezafibrate.
- 15 15. A pharmaceutical composition as claimed in claim 8 wherein the additional therapeutic agent is an antidiabetic agent selected from the group consisting of a biguanide, a glucosidase inhibitor, a meglitinide, a sulfonylurea, a thiazolidinedione, a peroxisome proliferator-activator receptor (PPAR)-alpha agonist, a peroxisome proliferator-activator receptor (PPAR)-gamma agonist, a peroxisome proliferator-activator receptor (PPAR) alpha/gamma dual agonist, a sodium glucose co-transporter (SGLT) 1, 2 or 3 inhibitor, a glycogen phosphorylase inhibitor, an aP2 inhibitor, a glucagon-like peptide-1 (GLP-1), a dipeptidyl peptidase IV inhibitor, a glucocorticoid (GR) antagonist and insulin.
- 20 16. A pharmaceutical composition as claimed in claim 8 wherein the additional therapeutic agent is an antidiabetic agent selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, troglitazone, pioglitazone, englitazone, darglitazone, rosiglitazone and insulin.
- 25

17. A pharmaceutical composition as claimed in claim 8 wherein the additional therapeutic agent is an anti-obesity agent is selected from the group consisting of an aP2 inhibitor, a peroxisome proliferator-activator receptor (PPAR) gamma antagonist, a peroxisome proliferator-activator receptor (PPAR) delta agonist, a beta-3 adrenergic agonist, a lipase inhibitor, a serotonin reuptake inhibitor and an anorectic agent.
- 5

Abstract

The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of 5 such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor.

